Anticancer and Apoptotic-Inducing Effects of Rutin-Chitosan Nanoconjugates in Triple Negative Breast Cancer Cells

Cancer includes a range of diseases that arise as a result of the unregulated growth of malignant cells, which have the potential to invade or spread to other body parts. Nanoparticles and drug conjugate systems enable unique approaches for cancer treatment. The present study focused on anti-breast cancer activity of rutin-chitosan nanoconjugates in in vitro system. Rutin-chitosan nanoconjugates were prepared by ionic gelation process and characterized by UV-Vis Spectra analysis, DLS, SEM, Zeta potential, FT-IR and XRD analysis. Further the nanoconjugates was evaluated for its anti-cancer activity on Triple Negative Breast Cancer (TNBC), it shows significant activity against selected breast cancer cells. The Inhibitory concentration (IC50) of synthesized nano-conjugate was found to be 12.5 mu g/mL. Furthermore, we found noteworthy cell cycle arrest at DNA synthetic phase following apoptotic cell deaths which were evidenced by AO/EtBr and DAPI fluorescence micrographic analysis. Our findings apparently validate that synthesized nano-conjugates could efficiently initiate the apoptotic process in the triple negative breast cancer cells. Through this finding, it is evidenced that the synthesized nanoconjugates potential applications in anti-cancer therapies.

Automated summary

The study focused on the anti-breast cancer activity of rutin-chitosan nanoconjugates, which showed significant activity against Triple Negative Breast Cancer (TNBC) cells with an IC50 of 12.5 μg/mL. The nanoconjugates also induced cell cycle arrest and apoptotic cell deaths, suggesting their potential application in anti-cancer therapies.